Previous 10 | Next 10 |
Pulmatrix (NASDAQ:PULM) said it regained compliance with the applicable Nasdaq minimum bid price continued listing requirement. PULM had previously been notified by Nasdaq on Aug. 17 that it was not in compliance with the minimum bid price rule. To regain compliance, TRIN was required to main...
Pulmatrix Regains Compliance With Nasdaq Listing Requirements PR Newswire LEXINGTON, Mass. , March 17, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious p...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Woah! It looks like Pulmatrix ( NASDAQ: PULM ) stock is up a gravity-defying 1,800% today as the tiny pharmaceutical company executes a 1-for-20 reverse stock split. Source: Shutterstock So what do you need t...
Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline PR Newswire LEXINGTON, Mass. , March 1, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled ther...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investor! It’s time to get into the thick of it with the biggest pre-market stock movers for Tuesday! Source: Eric Urquhart/Shutterstock.com Moving stocks this morning are reverse stock splits, ...
Pulmatrix (NASDAQ:PULM) trades 14.4% down after hours on announcing a 1-for-20 reverse split of its common stock, effective Feb.28, 2022 after market close. The stock is expected to trade on the Nasdaq on a split-adjusted-basis when the market opens on Mar. 1, 2022. T...
Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split PR Newswire LEXINGTON, Mass. , Feb. 24, 2022 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM) a clinical stage biopharmaceutical company developing innovative inhaled...
Pulmatrix Issues Letter to Stockholders PR Newswire LEXINGTON, Mass. , Feb. 1, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmona...
Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering PR Newswire LEXINGTON, Mass. , Dec. 17, 2021 /PRNewswire/ -- Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix" or the "Company"), a clinical stage biopharmaceutical company developing innovative in...
Pulmatrix (NASDAQ:PULM) is down -25.23% pre-market after announcing an offering of 6,745 shares of convertible preferred stock and warrants to purchase up to 5,620,834 shares of common stock. The shares of preferred stock will have a stated value of $1,000 per share and are converti...
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation PR Newswire Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket ® inhalation device. Pulmatrix transferring leased building,...
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) PR Newswire Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) a...